HTB

Conference reports

No neural tube defects among pregnancies with periconception dolutegravir exposure in the Dolomite-EPPICC cohort study

Conference on Retroviruses and Opportunistic Infections (CROI 2020)

CROI 2020: Special session on COVID-19

Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally

Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women

London patient is second person to be cured of HIV from allogeneic stem-cell transplant

The London Patient tells his story as second person cured of HIV

17th European AIDS Conference (EACS 2019)

Long-acting cabotegravir and rilpivirine: similar results in women and men 

Antiretroviral pregnancy registry: dolutegravir update

Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis

No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP

17th European AIDS Conference (EACS 2019)

Capsid inhibitor GS-6207: potential for 6 monthly dosing for MDR HIV

Dolutegravir/lamivudine as dual ART

Weight changes with doravirine-based first line therapy

Bone and renal changes in the ADVANCE trial

10th International Workshop on HIV and Ageing

Featured Impact of isolation and loneliness on older people living with HIV

17th European AIDS Conference (EACS 2019)

EACS launch major update to European Treatment Guidelines (November 2019)

Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial

10th International Workshop on HIV and Ageing

Frailty in HIV care and the importance of lifestyle changes

Research into use of medicinal cannabis in HIV management

Vaping can help HIV positive smokers who are not motivated to quit cigarettes

IDWeek (2019), 2–6 October 2019, Washington DC

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

Switching from TDF to TAF linked to higher BMI and cardio risk

Possible higher diabetes risk with raltegravir or PIs than NNRTIs

Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

Over half of mostly black US HIV group has NAFLD – and many have NASH

People taking more medications and women have higher fall risk in older HIV group

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

PrEP linked to lower HIV incidence in US, independent of TasP

10th IAS Conference on HIV Science (IAS 2019): final reports

Low rates of pregnancy with three methods of contraception in the ECHO trial

Other pregnancy studies IAS 2019

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

Dolutegravir for younger children: results from the ODYSSEY trial

PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

WHO recommends dolutegravir-based ART regimens for all

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

Fostemsavir: 96-week follow-up in people with multi-drug resistance

Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

Upcoming 10th IAS Conference on HIV Science (IAS 2019)

IAS 2019: late breaker highlights to look for

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs

Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine

Post navigation